You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed T cell Non-Hodgkin Lymphoma

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial in Miami (Mosunetuzumab,

Not yet recruiting
  • Refractory Non-Hodgkin Lymphoma
  • +2 more
  • Miami, Florida
    University of Miami
Aug 3, 2022

T-cell Non-Hodgkin Lymphoma, Lymphoma, Extranodal NK-T-Cell Trial in Busan, Daegu (Busulfan, Fludarabine)

Recruiting
  • T-cell Non-Hodgkin Lymphoma
  • Lymphoma, Extranodal NK-T-Cell
  • Busan, Korea, Republic of
  • +1 more
Aug 17, 2022

Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides Trial in United

Recruiting
  • Folliculotropic Mycosis Fungoides
  • +7 more
  • Durvalumab
  • +2 more
  • Duarte, California
  • +3 more
Jan 12, 2023

Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in United States (radiation,

Recruiting
  • Non-Hodgkin Lymphoma
  • +2 more
  • Bridging radiotherapy (BRT)
  • +2 more
  • Basking Ridge, New Jersey
  • +6 more
Jan 24, 2023

Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Tampa (Comprehensive Ablative Bridging Irradiation (CABI),

Recruiting
  • Large B-cell Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • Comprehensive Ablative Bridging Irradiation (CABI)
  • Chimeric Antigen Receptor T-Cell Therapy
  • Tampa, Florida
    Moffitt Cancer Center
Oct 26, 2023

NK/T Cell Lymphoma, Vascular Immunomother T Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Guangzhou (GNC-038)

Not yet recruiting
  • NK/T Cell Lymphoma
  • +2 more
  • Guangzhou, Guangdong, China
  • +1 more
Jan 12, 2023

CB-Long-Term Safety Study (CB-LTSS)

Enrolling by invitation
  • Lymphoma, Non-Hodgkin
  • +7 more
  • Allogeneic CAR-T therapy
  • Irvine, California
  • +3 more
Nov 18, 2022

Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia Trial in Philadelphia (BEAM-201)

Recruiting
  • Lymphoblastic Lymphoma
  • +2 more
  • BEAM-201
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jun 2, 2023

Non-hodgkin Lymphoma,B Cell Trial (CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection)

Not yet recruiting
  • Non-hodgkin Lymphoma,B Cell
  • CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection
  • (no location specified)
Feb 14, 2023

Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Spain (ARI0003)

Not yet recruiting
  • Refractory Non-Hodgkin Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • ARI0003
  • Santiago De Compostela, A Coruña, Spain
  • +6 more
Oct 24, 2023

B-cell Non-Hodgkin's Lymphoma Trial in Shanghai (Human CD19Targeted T Cells Injection)

Recruiting
  • B-cell Non-Hodgkin's Lymphoma
  • Human CD19Targeted T Cells Injection
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Jun 29, 2022

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Trial in Suzhou (Selinexor, Flu, CTX)

Recruiting
  • Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Apr 3, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +20 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 11, 2022

B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)

Recruiting
  • B-cell Lymphoma
  • +5 more
  • Louisville, Kentucky
    Norton Cancer Institute
Jan 24, 2023

Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston

Active, not recruiting
  • Anaplastic Large Cell Lymphoma
  • +4 more
  • Duarte, California
  • +3 more
Jul 21, 2022

Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in United States (IMPT-314)

Not yet recruiting
  • Relapsed Non-Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Los Angeles, California
  • +3 more
Apr 12, 2023

Acute T-lymphoblastic Leukemia, Acute T-lymphoblastic Lymphoma Trial in Xuzhou (CAR-T Cell Infusion)

Recruiting
  • Acute T-lymphoblastic Leukemia
  • Acute T-lymphoblastic Lymphoma
  • CAR-T Cell Infusion
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • BTK inhibitor
  • PD-1 inhibitor
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023

Non-Hodgkin Lymphoma Trial in Dallas (Focal radiation therapy (RT))

Recruiting
  • Non-Hodgkin Lymphoma
  • Focal radiation therapy (RT)
  • Dallas, Texas
    UT Southwestern Medical Center
Jul 8, 2022

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Trial in Suzhou (Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igß

Recruiting
  • Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
  • Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Apr 3, 2022

Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +15 more
  • Anti-CD19/CD20/CD22 CAR T-Cells
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 4, 2022

Cardiovascular Events Among Adults Relapsed or Refractory

Recruiting
  • Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
  • +9 more
  • Electronic Health Record Review
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Grade 1

Active, not recruiting
  • Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
  • +18 more
  • Anti-ICOS Monoclonal Antibody MEDI-570
  • +2 more
  • Duarte, California
  • +22 more
Jan 18, 2023

T-Acute Lymphoblastic Leukemia, Adult T Lymphoblastic Lymphoma Trial in United States (BL-8040, Nelarabine)

Terminated
  • T-Acute Lymphoblastic Leukemia
  • Adult T Lymphoblastic Lymphoma
  • Saint Louis, Missouri
  • +1 more
Jan 18, 2023

Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin

Active, not recruiting
  • Adult Lymphocyte Depletion Hodgkin Lymphoma
  • +16 more
  • 6,8-bis(benzylthio)octanoic acid
  • bendamustine hydrochloride
  • Winston-Salem, North Carolina
  • +1 more
Apr 8, 2022